Fig. 8From: PELI1: key players in the oncogenic characteristics of pancreatic CancerPELI1 Promotes p53 Degradation through RPS3. A GO enrichment analysis reveals an association between RPS3 and p53 binding. B Increased rate of p53 and RPS3 degradation in the PELI1 overexpression group after CHX (20 μM) treatment. C PC cells transfected with HA-Ub, with or without Flag-PELI1 plasmid, show elevated ubiquitination of p53 after MG132 (20 μM) treatment. D Endogenous immunoprecipitation confirms the binding of RPS3 to p53. E Immunoprecipitation with or without Flag-PELI1 plasmid, utilizing p53 and MDM2 antibodies, indicates that PELI1 decreases the binding of p53 to RPS3, while increasing p53 binding to MDM2. F PC cells transfected with HA-Ub, with or without Flag-PELI1 and Myc-RPS3 plasmids, and treated with MG132 (20 μM), demonstrate reduced ubiquitination of p53 with RPS3 overexpression. G Multiplex fluorescent IHC evaluates the protein expression of PELI1, RPS3, and p53 in PC and paracancerous tissuesBack to article page